Cyclacel Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Cyclacel Pharmaceuticals, Inc. carries a market capitalization of 10.61M, placing it among publicly traded companies globally. Its enterprise value stands at -4.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.61M |
| Enterprise Value | -4.06M |
Share Statistics
Cyclacel Pharmaceuticals, Inc. currently has 1.58M shares outstanding.
| Shares Outstanding | 1.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 20.61, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 20.61 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.06 |
| P/FCF Ratio | -0.02 |
| P/OCF Ratio | -0.02 |
Enterprise Valuation
| EV / Sales | 458.43 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cyclacel Pharmaceuticals, Inc. maintains a current ratio of 5.77, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.77 |
| Quick Ratio | 5.69 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -101.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 986,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Cyclacel Pharmaceuticals, Inc.'s stock has declined approximately -96.6849% over the past 52 weeks. The 50-day moving average sits at 8.11, while the 200-day moving average is 44.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.6849% |
| 50-Day Moving Average | 8.11 |
| 200-Day Moving Average | 44.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cyclacel Pharmaceuticals, Inc. generated 10,000.00 in revenue and converted that into -6.41M in net income, yielding earnings per share of -10.27. EBITDA reached -10.35M, while operating income came in at -10.36M.
| Revenue | 10,000.00 |
| Gross Profit | N/A |
| Operating Income | -10.36M |
| Pretax Income | -5.42M |
| Net Income | -6.41M |
| EBITDA | -10.35M |
| EBIT | -10.36M |
| Earnings Per Share (EPS) | -10.27 |
Balance Sheet
Cyclacel Pharmaceuticals, Inc. holds 4.28M in cash and equivalents against 10,000.00 in total debt, resulting in a net debt position of -4.27M. Total book value stands at -441.78M, with working capital of 3.62M providing operational flexibility.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 10,000.00 |
| Net Debt | -4.27M |
| Equity (Book Value) | -441.78M |
| Book Value Per Share | -708.16 |
| Working Capital | 3.62M |
Cash Flow
Cyclacel Pharmaceuticals, Inc. produced -8.73M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.73M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.73M |
| FCF Per Share | -13.99 |
Margins
Cyclacel Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -103,580.00 and net profit margin of -64,080.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -103,580.00 |
| Pretax Margin | -54,220.00 |
| Profit Margin | -64,080.00 |
| EBITDA Margin | -103,550.00 |
Dividends & Yields
The company's payout ratio of 0.31 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 0.31 |
| Shareholder Yield | -3,464.16 |
| FCF Yield | -4,234.83 |
Stock Splits
Cyclacel Pharmaceuticals, Inc.'s most recent stock split took place on July 7, 2025 with a 15:1 split ratio.
| Last Split Date | 7/7/2025 |
| Split Ratio | 15:1 |
Scores
Cyclacel Pharmaceuticals, Inc. posts an Altman Z-Score of -147.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -147.15 |